Cyplasin Biomedical Ltd (CYPL.OB) Granted New U.S. Patent
Cyplasin Biomedical Ltd (CYPL.OB) announced that the company has been awarded a new U.S. Patent application entitled "Cytotoxic Cyplasin of the Sea Hare, Aplysia punctata, cDNA Cloning and Expression of Bioreactive Recombinants" earlier today. This patent, US 7,271,242 B2, was granted to cover the production of a cytotoxic protein by mammalian cells and the use these cells to treat cancer. Professor Christian Petzelt, Chief Scientific Officer of Cyplasin Biomedical Ltd., commented, "This patent is an important milestone to define our intellectual property for the production method of the cytotoxic cyplasin and related proteins and its application as a substance to…